Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M

Pulmonx Corp

2024-FY EPS reported -$1.44 revenue$83,789,000

Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).
Full year 2024 revenue $83.8M, up 22% YoY; net loss $56.4M ($1.44/shr) narrowed from $60.8M ($1.60/shr) in 2023.
Adjusted EBITDA loss improved to $31.3M in 2024 from $39.0M in 2023; gross margin stable at 74%.
Cash and equivalents $101.5M at year-end 2024; added 11 new U.S. Zephyr Valve treatment centers in Q4.
FY2025 revenue guidance $96-98M (15-17% growth); operating expenses $133-135M including $22M stock comp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.